2022至2024年浙江省两城市带状疱疹流行病学特征:基于区域健康信息平台的分析
基于浙江省区域健康信息平台,分析舟山市和绍兴市2022至2024年带状疱疹流行特征。共识别45 280例首次就诊病例,总体发病率3.18‰且呈上升趋势,女性、绍兴市及高龄人群发病率更高,44.51%伴并发症,40岁及以上人群疫苗整体接种率仅1.42‰。
要点
- 2022至2024年舟山和绍兴共45 280例首次就诊带状疱疹病例,总体发病率3.18‰,呈上升趋势(P<0.001)。
- 女性发病率高于男性(3.46‰比2.91‰),绍兴市高于舟山市(3.38‰比1.87‰),发病率随年龄增长而升高(均P<0.001)。
- 44.51%(20 157/45 280)患者伴并发症,最常见为带状疱疹后神经痛;40岁及以上人群疫苗整体接种率1.42‰。
核心结论
- 浙江省带状疱疹疾病负担较重,带状疱疹疫苗的接种率较低。
研究设计与样本
- 基于浙江省区域健康信息平台的回顾性数据分析,收集2022至2024年舟山市和绍兴市42家公立医疗机构和149家基层医疗卫生机构的门诊及住院带状疱疹病例信息。
- 通过身份证号从浙江省免疫规划智慧服务信息系统匹配疫苗接种记录,并获取两城市按年龄、性别及区县划分的常住人口数据。
主要发现
- 2022至2024年共识别45 280例首次就诊带状疱疹病例,平均年龄57.82岁,女性占52.69%,门诊病例占95.01%。
- 总体发病率3.18‰,呈上升趋势(P<0.001),全年均可发病未见明显季节性,发病率随年龄增长而升高(P<0.001)。
- 女性发病率高于男性(3.46‰比2.91‰,P<0.001),绍兴市发病率高于舟山市(3.38‰比1.87‰,P<0.001)。
- 44.51%(20 157/45 280)患者伴并发症,最常见为带状疱疹后神经痛;伴并发症者发病率低于不伴并发症者(1.41‰比1.76‰,P<0.001),但住院率(0.14‰比0.03‰,P<0.001)和复发率(27.43‰比6.69‰,P<0.001)均高于不伴并发症者。
- 40岁及以上人群带状疱疹疫苗整体接种率为1.42‰。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the epidemiological characteristics of herpes zoster (HZ) in Zhoushan and Shaoxing cities of Zhejiang Province from 2022 to 2024. Methods: The HZ data were obtained from the Zhejiang Regional Health Information Platform. Specifically, information was sourced from 42 public hospitals and 149 primary healthcare institutions in Zhoushan and Shaoxing, covering both outpatient and inpatient records (e.g., name, sex, date of birth, ID number, visit date, diagnosis code, admission/discharge dates, and medical expenses). Additionally, vaccination records were matched by ID number from the Zhejiang Immunization Planning Smart Service Information System, including vaccination date, dose, and manufacturer. Permanent resident population data for both cities were collected and stratified by age, sex, and district/county. Based on these data, the epidemiological characteristics of HZ, such as incidence rate, hospitalization rate, and recurrence rate, as well as the occurrence of complications and vaccination, were analyzed. Results: From 2022 to 2024, a total of 45 280 initial HZ cases were identified. The mean age of patients was 57.82 years, with 52.69% being female patients and 95.01% being outpatient cases. Notably, the overall incidence rate of HZ was 3.18‰, showing a significant upward trend (P<0.001). HZ occurred throughout the year without marked seasonality. The incidence rate increased with age (P<0.001). The incidence rate was higher in females than males (3.46‰ vs. 2.91‰, P<0.001) and also higher in Shaoxing than Zhoushan (3.38‰ vs. 1.87‰, P<0.001). Regarding complications, these occurred in 44.51% (20 157/45 280) of patients, with the most common complication being postherpetic neuralgia. The incidence rate of HZ with complications was lower than that without complications (1.41‰ vs. 1.76‰, P<0.001), but both hospitalization (0.14‰ vs. 0.03‰, P<0.001) and recurrence rates (27.43‰ vs. 6.69‰, P<0.001) were higher for cases with complications. Additionally, among individuals aged ≥40 years, the overall HZ vaccination rate was 1.42‰. Conclusion: Herpes zoster imposes a substantial disease burden in Zhejiang Province, while the vaccination rate remains low. 目的: 分析2022—2024年浙江省舟山市和绍兴市带状疱疹(HZ)的流行特征。 方法: HZ病例数据源自浙江省区域健康信息平台,收集2022—2024年舟山市和绍兴市42家公立医疗机构和149家基层医疗卫生机构的HZ病例信息,包括门诊及住院患者姓名、性别、出生日期、证件号码、就诊时间、诊断编码、入/出院时间、门/住院总金额等就诊信息。所有疫苗接种记录均以身份证号作为关键变量从“浙江省免疫规划智慧服务信息系统”进行匹配,获取疫苗接种时间、接种剂次、厂家等信息。同时,分别获取舟山市和绍兴市的总常住人口数据,包括按年龄、性别及区县划分的人口构成。对HZ的发病率、住院率和复发率等流行特征,以及并发症的发生情况和疫苗接种情况进行分析。 结果: 2022—2024年浙江省舟山市和绍兴市共发生45 280例首次就诊HZ病例,患者的平均年龄为57.82岁,52.69%为女性患者,95.01%为门诊病例。2022—2024年HZ总体发病率为3.18‰,发病呈上升趋势(P<0.001)。HZ全年均可发病,未见明显季节性。HZ的发病率随年龄增长而升高(P<0.001),女性发病率高于男性(3.46‰比2.91‰,P<0.001),绍兴市发病率高于舟山市(3.38‰比1.87‰,P<0.001)。44.51%(20 157/45 280)的HZ患者发生HZ时伴有并发症,最常见并发症为带状疱疹后神经痛。HZ伴并发症者的发病率低于不伴并发症者(1.41‰比1.76‰,P<0.001),但住院率(0.14‰比0.03‰,P<0.001)和复发率(27.43‰比6.69‰,P<0.001)均高于不伴并发症者。40岁及以上人群HZ疫苗整体接种率为1.42‰。 结论: 浙江省HZ疾病负担较重,HZ疫苗的接种率较低。.
引用
- Wang SY, Wang YD, Wang SJ, et al. [Epidemiological characteristics of herpes zoster in two cities of Zhejiang Province from 2022 to 2024: an analysis based on a regional health information platform]. Zhonghua Yu Fang Yi Xue Za Zhi. 2025. PMID: 41111280. doi:10.3760/cma.j.cn112150-20250722-00699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。